J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in
J&J’s third-line multiple myeloma blockbuster Darzalex got the FDA green light for a new regimen to take another swing at the blood cancer — this time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
